{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:05:26Z","timestamp":1784761526323,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.01.031","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:53:16Z","timestamp":1677106396000},"page":"2147-2154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines"],"prefix":"10.1016","volume":"41","author":[{"given":"Diana","family":"Kouiavskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mirochnitchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Troy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.031_b0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jiac130","article-title":"Polio by the numbers \u2013 a global perspective","volume":"226","author":"Badizadegan","year":"2022","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2023.01.031_b0010","first-page":"699","volume":"64","year":"2015","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2023.01.031_b0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.031_b0020","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.031_b0025","doi-asserted-by":"crossref","unstructured":"Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS ONE. 2013;8:e83374.","DOI":"10.1371\/journal.pone.0083374"},{"key":"10.1016\/j.vaccine.2023.01.031_b0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/erv.11.51","article-title":"Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains","volume":"10","author":"Verdijk","year":"2011","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2023.01.031_b0035","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.031_b0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1749-6632.1995.tb44462.x","article-title":"Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination","volume":"754","author":"Sutter","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2023.01.031_b0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0042-6822(61)90114-3","article-title":"Intratypic sero-differentiation of polioviruses","volume":"15","author":"Plotkin","year":"1961","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2023.01.031_b0050","first-page":"199","article-title":"Intratypic differentiation of poliovirus strains by enzyme-linked immunosorbent assay (ELISA): poliovirus type 1","volume":"55","author":"Glikmann","year":"1983","journal-title":"Dev Biol Stand."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2023.01.031_b0055","doi-asserted-by":"crossref","first-page":"S535","DOI":"10.1093\/clinids\/6.Supplement_2.S535","article-title":"Antigenic variation of poliovirus studied by means of monoclonal antibodies","volume":"6","author":"Crainic","year":"1984","journal-title":"Rev Infect Dis."},{"key":"10.1016\/j.vaccine.2023.01.031_b0060","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/424524","article-title":"Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy","volume":"190","author":"Dragunsky","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.031_b0065","doi-asserted-by":"crossref","unstructured":"Crawt L, Atkinson E, Tedcastle A, Pegg E, s IPVSG, Minor P, et al. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. J Infect Dis. 2020;221:544-52.","DOI":"10.1093\/infdis\/jiz076"},{"key":"10.1016\/j.vaccine.2023.01.031_b0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00430-012-0237-2","article-title":"Poor immunity status against poliomyelitis in medical students: a semi-anonymous study","volume":"202","author":"Kulshammer","year":"2013","journal-title":"Med Microbiol Immunol."},{"key":"10.1016\/j.vaccine.2023.01.031_b0075","doi-asserted-by":"crossref","DOI":"10.2807\/ese.15.47.19723-en","article-title":"Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010","volume":"15","author":"Grard","year":"2010","journal-title":"Euro Surveill."},{"key":"10.1016\/j.vaccine.2023.01.031_b0080","doi-asserted-by":"crossref","unstructured":"Drexler JF, Grard G, Lukashev AN, Kozlovskaya LI, Bottcher S, Uslu G, et al. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proceedings of the National Academy of Sciences of the United States of America. 2014;111:12889-94.","DOI":"10.1073\/pnas.1323502111"},{"key":"10.1016\/j.vaccine.2023.01.031_b0085","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu841","article-title":"Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults","author":"Troy","year":"2015","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2023.01.031_b0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/QAI.0000000000001079","article-title":"Effects of well-controlled HIV infection on complement activation and function","volume":"73","author":"Ebr","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2023.01.031_b0095","series-title":"Manual for the virological investigation of poliomyelitis","first-page":"1","author":"Who","year":"1997"},{"key":"10.1016\/j.vaccine.2023.01.031_b0100","series-title":"Guide for the Care and Use of Laboratory Animals","author":"Council","year":"2011"},{"key":"10.1016\/j.vaccine.2023.01.031_b0105","first-page":"497","article-title":"Maintenance and distribution of transgenic mice susceptible to human viruses: Memorandum from a WHO meeting","volume":"71","author":"World Health Organization","year":"1993","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2023.01.031_b0110","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1016\/j.vaccine.2007.07.027","article-title":"Influenza vaccine: the challenge of antigenic drift","volume":"25","author":"Carrat","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.031_b0115","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.031_b0120","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/cid\/cis714","article-title":"An outbreak of wild poliovirus in the Republic of Congo, 2010\u20132011","volume":"55","author":"Patel","year":"2012","journal-title":"Clin Infect Dis."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.01.031_b0125","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiu282","article-title":"Factors contributing to outbreaks of wild poliovirus type 1 infection involving persons aged >\/=15 years in the Democratic Republic of the Congo, 2010\u20132011, informed by a pre-outbreak poliovirus immunity assessment","volume":"210","author":"Alleman","year":"2014","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2023.01.031_b0130","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1016\/j.vaccine.2015.10.091","article-title":"Production of high titer attenuated poliovirus strains on the serum-free PER.C6((R)) cell culture platform for the generation of safe and affordable next generation IPV","volume":"33","author":"Sanders","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.01.031_b0135","doi-asserted-by":"crossref","first-page":"11970","DOI":"10.1038\/s41598-019-48534-1","article-title":"Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test","volume":"9","author":"Arita","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.01.031_b0140","first-page":"TRS993","article-title":"Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated)","author":"Who","year":"2015","journal-title":"Tech Rep Ser"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2300052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:40Z","timestamp":1759404340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2300052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X2300052X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}